ClinConnect ClinConnect Logo
Search / Trial NCT01239953

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)

Launched by FUNDACIÓN MÉDICA PARA LA INVESTIGACIÓN Y DESARROLLO EN EL AREA CARDIOVASCULAR · Nov 12, 2010

Trial Information

Current as of June 24, 2025

Unknown status

Keywords

In Stent Restenosis Drug Eluting Balloon Drug Eluting Stent Angiography Minimal Lumen Diameter

ClinConnect Summary

Treatment of patients with bare metal stent restenosis remains a major clinical and technical challenge. Currently, drug-eluting stents are widely used in the management of these patients. Recently, the value of the paclitaxel-eluting balloon in this clinical setting has been suggested. However, there is only scarce observational data on the value of this new balloon in patients with bare metal stent restenosis.

This prospective, multicenter, randomized clinical trial will compare two different interventional strategies (namely, paclitaxel-eluting balloon vs everolimus-eluting stent) in th...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • PATIENT:
  • Age between 20 and 85 years
  • Signed informed consent
  • Acceptance of late angiographic control (6-9 months)
  • Angina and / or objective evidence of ischemia
  • LESION:
  • In-Stent restenosis (\> 50% visual) any bare metal stent
  • Knowledge of prior stent location
  • Exclusion Criteria:
  • PATIENT:
  • Inclusion in another clinical research protocol
  • Women of childbearing age
  • Severe associated systemic disease (including renal or liver failure)
  • Severe depression of left ventricular ejection fraction (LVEF \<25%)
  • Disease that affects life expectancy
  • Recent myocardial infarction ( \<7 days)
  • Time of implantation of the previous BMS \<1 month
  • Severe difficulties expected for late angiographic study
  • LESION:
  • Angiographic failure during implementation of initial stent(residual stenosis\> 50%)
  • Image of large thrombus in-stent (\> vessel diameter)
  • Tortuosity or Ca + + with very severe difficulties during prior stent deployment
  • Vessel diameter \<2 mm (visual estimate)
  • Restenosis only "outside" the stent (The edge of the stent is not affected)
  • Completely occlusive restenosis (100%, TIMI 0)
  • Very diffuse restenosis (\> 30 mm length)

About Fundación Médica Para La Investigación Y Desarrollo En El Area Cardiovascular

The Fundación Médica para la Investigación y Desarrollo en el Área Cardiovascular is a leading clinical trial sponsor dedicated to advancing cardiovascular health through innovative research and development. Committed to enhancing patient outcomes, the foundation focuses on conducting rigorous clinical studies that explore novel therapies and interventions in the cardiovascular field. With a multidisciplinary team of experts, the foundation fosters collaboration among healthcare professionals, researchers, and industry partners, ensuring the highest standards of scientific integrity and patient safety. Through its initiatives, the foundation aims to contribute significantly to the understanding and treatment of cardiovascular diseases, ultimately improving the quality of life for patients worldwide.

Locations

Madrid, , Spain

Valencia, , Spain

Madrid, , Spain

Zaragoza, , Spain

Malaga, , Spain

Barcelona, , Spain

Madrid, , Spain

Alicante, , Spain

Valencia, , Spain

A Coruña, , Spain

Santander, Cantabria, Spain

Granada, , Spain

Madrid, , Spain

Barcelona, , Spain

Barcelona, , Spain

Barcelona, , Spain

Oviedo, Asturias, Spain

Zaragoza, , Spain

L'hospitalet De Llobregat, Barcelona, Spain

Majadahonda, Madrid, Spain

Almeria, , Spain

Palma De Mallorca, Illes Balears, Spain

Pamplona, Navarra, Spain

Vigo, Pontevedra, Spain

Badajoz, , Spain

Malaga, , Spain

Toledo, , Spain

Patients applied

0 patients applied

Trial Officials

Fernando Alfonso, MD, PhD

Study Director

Hospital San Carlos, Madrid

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials